Nuvalent, Inc.

NASDAQ:NUVL

Biotechnology

Healthcare
$123.96 -0.02%

-$0.03 today

Market cap
$9.13B
Beta
1.15
P/E (TTM)
-21.6
EPS (TTM)
-$5.72
52W Low $71.13High $123.62

Volume 0.00M

Average 1.91M

NUVL Total Assets

Everything the company owns or controls; equal to total liabilities plus equity.

Nuvalent, Inc.NASDAQ: NUVL

Total Assets · Q1 FY2026 · quarter ended Mar 2026

Total assets rises 20.4% from a year ago

Total assets stood at $1.33B at the end of Q1 FY2026, up 20.4% from a year earlier and down 5.8% from the prior quarter. Over 3 fiscal years it compounded at +43.1% a year.

Context

  • Total assets increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total assets keeps rising in the next quarterly balance sheet after a +20.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.33B-5.8% QoQ
Last fiscal yearDec 2025
$1.41B+23.7% YoY
Year agoMar 2025
$1.11B+20.4% since
Total Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.4%——
1 year+23.7%——
3-year CAGR+43.1%——
5-year CAGR——
10-year CAGR——

Total Assets history

USD · from the balance sheet

Latest · FY2025
1.41B USD
Year-over-year change
+23.7%
4-year CAGR
+48.1%

Total Assets vs competitors

How NUVL compares with its peers on the latest reported figures

  • Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +20.4% is the 4th highest of 9, against a peer median of +16.4%.
  • Over three fiscal years its annual growth of +43.1% compares with a peer median of +19.8%.
NUVL Competitors
Total Assets for NUVL and competitors
Company Period Latest balance YoY 3-year CAGR
JAZZJazz Pharmaceuticals plcSep 2026$12B USD+5.6%+2.5%
PCVXVaxcyte, Inc.Jun 2026$3.14B USD-5.1%+44.7%
CRSPCRISPR Therapeutics AGSep 2026$2.56B USD+13.9%+0.3%
CYTKCytokinetics, IncorporatedJun 2026$1.92B USD+57.0%+12.0%
ARWRArrowhead Pharmaceuticals, Inc.Sep 2026$1.74B USD+25.5%+31.4%
NUVLNuvalent, Inc.Mar 2026$1.33B USD+20.4%+43.1%
AXSMAxsome Therapeutics, Inc.Jun 2026$761.45M USD+19.0%+27.7%
ABVXAbivax S.A.Jun 2026€462.21M EUR+286.3%+97.7%
RYTMRhythm Pharmaceuticals, Inc.Sep 2026$443.13M USD-12.6%+7.9%
Peer median (excluding NUVL) —+16.4%+19.8%

Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents68.53M241.81M335.39M145.69M261.75M
Short-term Investments219.59M230.36M384.52M972.61M1.11B
Net Receivables00000
Inventory00000
Other Current Assets05.83M6.58M14.15M0
Total Current Assets290.63M477.99M726.49M1.13B1.39B
Property, Plant & Equipment (Net)00000
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets3.2M4.47M5.9M9.3M20.28M
Total Non-current Assets3.2M4.47M5.9M9.3M20.28M
Total Assets293.82M482.46M732.38M1.14B1.41B
Account Payables2.89M7.2M9.27M5.23M30.16M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities3.16M7.43M7.33M10.45M16.94M
Total Current Liabilities8.79M19.48M31.82M54.02M91.17M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00017.94M73.2M
Total Non-current Liabilities00017.94M73.2M
Total Liabilities8.79M19.48M31.82M71.96M164.37M
Common Stock5K6K7K8K8K
Retained Earnings(78.22M)(160.08M)(286.3M)(547.05M)(972.43M)
Accumulated OCI(228K)(494K)31K(59K)2.35M
Other Stockholders Equity00000
Minority Interest00000
Total Equity285.04M462.98M700.56M1.07B1.25B
Total Debt00000
Net Debt(68.53M)(241.81M)(335.39M)(145.69M)(261.75M)

Nuvalent, Inc.

NASDAQ:NUVL

Intrinsic Alpha fair value

Locked

Current Price

$123.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.